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Abstract Fatty acids induce apoptosis in primary astrocytes by
enhancing ceramide synthesis de novo. The possible role of the
AMP-activated protein kinase (AMPK) in the control of
apoptosis was studied in this model. Long-term stimulation of
AMPK with 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR) prevented apoptosis. AICAR blunted fatty acid-
mediated induction of serine palmitoyltransferase and ceramide
synthesis de novo, without affecting fatty acid synthesis and
oxidation. Prevention of ceramide accumulation by AICAR led
to a concomitant blockade of the Raf-1/extracellular signal-
regulated kinase cascade, which selectively mediates fatty acid-
induced apoptosis. Data indicate that AMPK may protect cells
from apoptosis induced by stress stimuli. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Mammalian AMP-activated protein kinase (AMPK) be-
longs to a family of protein kinases that has been highly
conserved throughout evolution in animals, plants and yeast,
and which plays a major role in cell response to metabolic
stress [1,2]. AMPK is activated by AMP and by phosphory-
lation by an upstream kinase, which is itself activated by
AMP. Once activated, AMPK phosphorylates and inactivates
a number of regulatory enzymes involved in biosynthetic
pathways. The AMPK cascade seems to have evolved to mon-
itor the energy status of the cell and to initiate appropiate
energy-conserving mechanisms in response to ATP depletion
during metabolic stress [1,2]. One of the most intriguing and
unexplored actions of AMPK is its possible anti-apoptotic
e¡ect. Thus, two previous reports have shown that pharma-
cological activation of AMPK protects thymocytes from dex-
amethasone-induced apoptosis [3] and Rat-1 ¢broblasts from
serum withdrawal-induced apoptosis [4]. However, the poten-
tial pathophysiological implications of these ¢ndings are ham-
pered by the absolute lack of knowledge of the underlying
mechanisms.
The present work was therefore undertaken to study the
mechanism of the anti-apoptotic e¡ect of AMPK in neural
cells. One of the most important mediators of apoptosis in
the central nervous system is ceramide. Thus, ceramide accu-
mulation occurs in cultured neural cells exposed to stress stim-
uli, as well as in the brain in neurodegenerative disorders such
as Alzheimer’s disease, Parkinson’s disease, epilepsy and is-
chemia/stroke [5,6]. Moreover, changes in ceramide metabo-
lism exert important regulatory e¡ects on neuronal growth
and development [7]. We have recently developed a model
in which exposure of primary astrocytes to fatty acids leads
to apoptosis selectively via de novo-synthesized ceramide [8].
By using this model we sought to answer two questions: (a)
does AMPK activation prevent ceramide-induced apoptosis?;
(b) if so, which may be the targets of AMPK action?
2. Materials and methods
2.1. Cell culture
Cortical astrocytes were derived from 24 h old Wistar rats and
cultured as described before [9]. For all the experimental determina-
tions performed, the serum-containing medium was removed and cells
were transferred to a chemically de¢ned, serum-free medium consist-
ing of DMEM/Ham’s F12 (1:1, v/v) supplemented with 5 Wg/ml in-
sulin, 50 Wg/ml human transferrin, 20 nM progesterone, 50 WM pu-
trescine, 30 nM sodium selenite and 1.0% (w/v) defatted and dialyzed
bovine serum albumin.
2.2. Cell death
Cell viability was determined by trypan blue exclusion. For Hoechst
33258 staining, cells were grown in glass coverslips and ¢xed (20 min
at room temperature) with 4% paraformaldehyde in phosphate-bu¡-
ered saline supplemented with 5% sucrose. The dye was applied at a
¢nal concentration of 16 Wg/ml and cells were examined by £uores-
cence microscopy.
2.3. Rates of metabolic pathways
(a) Sphingolipid synthesis: reactions were started by the addition of
1 WCi L-[U-14C]serine, and stopped with 1 ml methanol at the times
indicated. Lipids were extracted and saponi¢ed, and ceramide and
sphingomyelin were resolved by thin layer chromatography [8,10].
(b) Fatty acid oxidation: reactions were started by the addition of
0.2 mM (0.3 WCi) albumin-bound [1-14C]palmitate plus 0.5 mM
L-carnitine, and stopped with 0.3 ml 2 M HClO4 after 2 h. Oxidation
products were extracted and quanti¢ed exactly as described before [9].
(c) Fatty acid synthesis: reactions were started by the addition of
4 mM (1.0 WCi) [1-14C]acetate, and stopped with 0.2 ml 10 M
NaOH after 6 h. Samples were saponi¢ed and fatty acids were ex-
tracted with light petroleum ether [11].
2.4. Protein kinase activities
(a) AMPK: cells were lysed, supernatants were obtained, and
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AMPK activity was determined as the incorporation of [Q-32P]ATP
into the speci¢c SAMS peptide substrate [11]. (b) Extracellular signal-
regulated kinase (ERK): cells were lysed, supernatants were obtained,
and ERK activity was determined as the incorporation of [Q-32P]ATP
into a speci¢c peptide substrate [10]. (c) Raf-1: after Raf-1 immuno-
precipitation, Raf-1 kinase activity was determined as the incorpora-
tion of [Q-32P]ATP into kinase-negative MEK1(97A) [10].
2.5. Other enzyme activities and levels
(a) Serine palmitoyltransferase (SPT): enzyme activity was deter-
mined in digitonin-permeabilized astrocytes as the incorporation of
radiolabelled L-serine into ketosphinganine by a new procedure.
Thus, the medium was aspirated and cells were washed twice with
phosphate-bu¡ered saline. Reactions were started by the addition of
100 mM HEPES, pH 8.3, 200 mM sucrose, 2.5 mM EDTA, 5 mM
dithioerythritol, 50 WM pyridoxal phosphate, 1.0 mg/ml defatted and
dialyzed bovine serum albumin, 15 Wg/ml digitonin, 0.3 mM palmito-
yl-CoA and 0.25 mM L-[U-14C]serine (3 WCi/assay). After 45 min,
reactions were stopped with 0.5 M NH4OH and [14C]ketosphinganine
product was extracted with chloroform/methanol/1% NaCl [12]. Pre-
liminary experiments de¢ned the optimal concentration of palmitoyl-
CoA, serine and digitonin in the assay, as well as its linearity with
time. The validity of the assay was proved by the full inhibitory e¡ect
exerted by the SPT competitive inhibitor L-cycloserine. Western blot
analysis was carried out with a polyclonal antibody raised against
hamster SPT LCB2 catalytic subunit [13]. (b) Carnitine palmitoyl-
transferase I (CPT-I): enzyme activity was determined in digitonin-
permeabilized astrocytes as the tetradecylglycidate-sensitive incorpo-
ration of L-[Me-3H]carnitine into palmitoylcarnitine by method A
(‘one-step assay’) described in [11]. Western blot analysis was carried
out with a polyclonal antibody raised against rat liver CPT-I [9].
(c) Acetyl-CoA carboxylase (ACC): enzyme activity was determined
in digitonin-permeabilized astrocytes as the incorporation of [1-14C]-
acetyl-CoA into fatty acids in a reaction coupled to the fatty acid
synthase reaction [9]. Mass measurement of ACC was performed by
avidin-based enzyme-linked immunosorbent assay analysis using a
polyclonal antibody raised against rat liver ACC [14].
2.6. Statistical analysis
Results shown represent the means þ S.D. of the number of experi-
ments indicated in every case. Statistical analysis was performed by
ANOVA. A post hoc analysis was made by the Student^Neuman^
Keuls test.
3. Results
3.1. Long-term AMPK stimulation prevents fatty acid-induced
apoptosis
We have previously shown that exposure of primary astro-
cytes to palmitate leads to apoptosis [8]. Astrocytes were ex-
posed to palmitate at a concentration physiologically relevant
in brain, and cell viability was determined at di¡erent times.
As shown in Fig. 1, palmitate induced the death of astrocytes
in a time-dependent fashion. Prolonged exposure to 5-amino-
imidazole-4-carboxamide ribonucleoside (AICAR), a selective
cell-permeable activator of AMPK which has been widely
used to demonstrate the implication of this kinase in the reg-
ulation of cellular processes [1], was able to prevent com-
pletely palmitate-induced cell death, as determined by both
trypan blue exclusion (Fig. 1A) and Hoechst 33258 staining
(Fig. 1B). In our cultured astrocyte system, incubation with
0.2 mM AICAR for 48 h activated AMPK by 47 þ 14% (n = 3,
P6 0.01 vs. incubations with no additions).
3.2. Long-term AMPK stimulation prevents ceramide synthesis
de novo and SPT induction
Fatty acid-induced apoptosis of astrocytes occurs selectively
by enhanced ceramide synthesis de novo [8]. As shown in
Table 1, palmitate notably stimulated ceramide synthesis de
Fig. 1. Palmitate-induced death of astrocytes: prevention by
AICAR. (A) Cell viability. Cells were incubated for the times indi-
cated with 0.2 mM palmitate in the absence (a) or presence (b) of
0.2 mM AICAR, or with 0.2 mM AICAR alone (E). Results are ex-
pressed as percentage of incubations with no additions, and were
obtained from four di¡erent experiments. (B) Hoechst 33258 stain-
ing. Cells were incubated for 48 h in the absence or presence of
0.2 mM palmitate (C16:0) and/or 0.2 mM AICAR. A representative
experiment is shown. Similar results were obtained in two other ex-
periments. Arrows point to condensed or fragmented nuclei.
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novo. By contrast, no signi¢cant e¡ect of palmitate on serine
incorporation into sphingomyelin was evident. AICAR
blunted palmitate-induced ceramide generation without exert-
ing any e¡ect on sphingomyelin synthesis. To further support
the involvement of AMPK in the control of ceramide syn-
thesis de novo we determined the activity of SPT, which cata-
lyzes the pace-setting step of this pathway. Thus, AICAR
prevented palmitate-mediated SPT induction, as determined
by both Western blot (Fig. 2A) and assay of enzyme activity
(Fig. 2B). Relative levels of SPT expression, as determined by
densitometric analysis of the bands in the Western blots, were
1.00 (no additions), 1.37 þ 0.14 (48 h exposure to 0.2 mM
palmitate), 1.01 þ 0.09 (48 h exposure to 0.2 mM AICAR),
and 0.91 þ 0.15 (48 h exposure to 0.2 mM palmitate and
0.2 mM AICAR) (n = 4).
3.3. Long-term AMPK stimulation prevents Raf-1/ERK
activation
We have previously shown that de novo-synthesized ceram-
ide signals apoptosis in primary astrocytes via activation of
the Raf-1/ERK cascade [8]. The e¡ect of AICAR on the ac-
tivity of these two kinases was therefore determined. The pal-
mitate-induced activation of ERK (Fig. 3A) and Raf-1 (Fig.
3B) was prevented by AICAR. Although AMPK has been
shown to phosphorylate a Raf-1 peptide in vitro [15], incuba-
tion of astrocytes with AICAR alone did not a¡ect basal
ERK and Raf-1 activities.
3.4. Long-term AMPK stimulation does not a¡ect fatty acid
catabolism
AMPK stimulation enhances fatty acid oxidation in astro-
cytes [11] and other cells such as myocytes and hepatocytes
[1,2]. It might therefore be argued that AICAR prevents cer-
amide accumulation by diverting palmitate into the oxidative
pathway. However, this is not the case in our experimental
system. Although rapid (minute range) AMPK stimulation
with AICAR does enhance fatty acid oxidation and blunt
fatty acid synthesis in astrocytes [11], these alterations return
to basal levels after prolonged (day range) AICAR challenge.
Table 1
Palmitate-induced ceramide synthesis and astrocyte death: prevention by AICAR
Additions Viable cells (%) L-[14C]serine into lipid
Ceramide (%) Sphingomyelin (%)
None 100 þ 8 100 þ 18 100 þ 14
C16:0 72 þ 7a 217 þ 36a 109 þ 25
AICAR 101 þ 9 93 þ 21 94 þ 8
C16:0+AICAR 95 þ 8 127 þ 34 91 þ 15
Cells were incubated for 48 h in the absence or presence of 0.2 mM palmitate (C16:0) and/or 0.2 mM AICAR. Results are expressed as per-
centage of incubations with no additions, and were obtained from six di¡erent experiments. 100% values of L-[14C]serine incorporation into cer-
amide and sphingomyelin were 0.77 and 3.06 nmol per 24 h per mg cell protein, respectively.
aSigni¢cantly di¡erent (P6 0.01) from the respective incubations with no additions.
Fig. 2. Palmitate-mediated induction of SPT and CPT-I: di¡erential
e¡ect of AICAR. Cells were incubated for 48 h in the absence or
presence of 0.2 mM palmitate (C16:0) and/or 0.2 mM AICAR.
(A) SPT and CPT-I expression. A representative Western blot is
shown. (B) SPT activity. (C) CPT-I activity. Results in (B) and (C)
are expressed as percentage of incubations with no additions, and
were obtained from four di¡erent experiments. Signi¢cantly di¡erent
from incubations with no additions: *P6 0.05; **P6 0.01.
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Thus, no signi¢cant e¡ect of 48 h AICAR exposure was evi-
dent on the rate of fatty acid oxidation and fatty acid syn-
thesis (data not shown), and on the activity and levels of the
pace-setting enzymes of these two pathways, CPT-I (Fig.
2A,C) and ACC (data not shown), respectively. Relative levels
of CPT-I expression, as determined by densitometric analysis
of the bands in the Western blots, were 1.00 (no additions),
1.61 þ 0.20 (48 h exposure to 0.2 mM palmitate), 1.05 þ 0.14
(48 h exposure to 0.2 mM AICAR), and 1.64 þ 0.11 (48 h
exposure to 0.2 mM palmitate and 0.2 mM AICAR) (n = 4).
4. Discussion
The hypothesis that ceramide acts as a second messenger in
the induction of apoptosis has attracted a lot of attention
during the last few years. It is usually considered that ceram-
ide generation through sphingomyelin hydrolysis by neutral
and/or acid sphingomyelinase is the norm in ceramide signal-
ing pathways leading to apoptosis. The link between receptor
activation, sphingomyelinase stimulation and ceramide gener-
ation is mostly supported by comprehensive studies on the
p55 tumor necrosis factor receptor, the p75 neurotrophin re-
ceptor and CD95/Fas [16,17]. In addition, other stress stimuli
of chemical, physical, bacterial and viral origin may induce
apoptosis by evoking changes in the sphingomyelin/ceramide
cycle [16,17]. However, the de novo synthesis pathway has
been gaining appreciation as an alternative means of generat-
ing an apoptotic pool of ceramide. Thus, a signi¢cant contri-
bution of the de novo pathway to ceramide generation and
apoptosis has been reported in a number of paradigms em-
ploying cultured neural (e.g. [8,10,18]) and non-neural cells
(e.g. [19^21]). In particular, because palmitate is a precursor
for ceramide synthesis de novo, it is conceivable that its ac-
cumulation may lead to increased ceramide synthesis and ap-
optosis, as evidenced in hematopoietic cells [22], pancreatic L
cells [23] and astrocytes [8].
Work by Bazan in the early 70s demonstrated an enhanced
breakdown of cellular glycerolipids and a concomitant accu-
mulation of non-esteri¢ed fatty acids ^ including palmitic acid
^ in a number of models of brain trauma/ischemia [24,25]. The
breakdown of membrane phospholipids on trauma/ischemia
seems to be the result of Ca2-induced stimulation of phos-
pholipases and of impairment of phospholipid resynthesis ow-
ing to energy depletion, and may be involved in irreversible
damage of membrane structure and function [26]. In addition,
non-esteri¢ed fatty acids exert various detrimental e¡ects on
brain structure and function such as uncoupling of oxidative
phosphorylation; disruption of plasma membrane and mito-
chondrial ion £uxes; inhibition of membrane receptors, en-
zymes and ion channels; and elevation of synaptic glutamate
concentration [26]. Hence our data indicate that ceramide syn-
thesized de novo from non-esteri¢ed fatty acids may contrib-
ute to the apoptotic death of astrocytes in situations of brain
trauma/ischemia. AMPK is expressed in brain [27^29], but its
function in this organ is as yet unknown. Because in astro-
cytes (a) AMPK is stimulated in hypoxic [11] and gliotic states
[30], and (b) AMPK activation prevents fatty acid-evoked
SPT induction, stimulation of ceramide synthesis de novo
and apoptosis (the present report), data also suggest that
the balance between pro-apoptotic fatty acid accumulation
and anti-apoptotic AMPK stimulation might determine cer-
amide levels and therefore in£uence the cell survival/death
decision. In line with other studies showing that AMPK con-
trols gene expression [31,32], cytoskeletal dynamics [33] and
cell death [3,4], the present report supports the emerging no-
tion that AMPK regulates not only energy metabolism but a
much wider array of cellular functions.
Acknowledgements: We are indebted to Dr. D. Carling (Hammer-
smith Hospital, Medical Research Council, London, UK), Dr. K.
Hanada (National Institute of Infectious Diseases, Tokyo, Japan),
Dr. J.M. Lowenstein (Brandeis University, Waltham, MA, USA)
and Dr. V.A. Zammit (Hannah Research Institute, Ayr, UK) for
kindly donating the SAMS peptide, the anti-SPT antibody, the tetra-
decylglycidate and the anti-CPT-I antibody, respectively. This work
was supported by Grants from Comisio¤n Interministerial de Ciencia y
Tecnolog|¤a (PM 98/0079) and Comunidad Auto¤noma de Madrid
(CAM 08.5/0017/98), and by the Netherlands Foundation for Chem-
Fig. 3. Palmitate-induced activation of ERK and Raf-1 in astro-
cytes: prevention by AICAR. Cells were incubated for 48 h in the
absence or presence of 0.2 mM palmitate (C16:0) and/or 0.2 mM
AICAR. Results are expressed as percentage of incubations with no
additions, and were obtained from four di¡erent experiments. (A)
ERK activity. (B) Raf-1 activity. Signi¢cantly di¡erent from incuba-
tions with no additions: *P6 0.05; **P6 0.01.
FEBS 24540 25-1-01
C. Bla¤zquez et al./FEBS Letters 489 (2001) 149^153152
ical Research (SON) with ¢nancial aid from the Netherlands Organi-
zation for Scienti¢c Research (NOW).
References
[1] Hardie, D.G., Carling, D. and Carlson, M. (1998) Annu. Rev.
Biochem. 67, 821^855.
[2] Kemp, B.E., Mitchelhill, K.I., Stapleton, D., Michell, B.J., Chen,
Z.P. and Witters, L.A. (1999) Trends Biochem. Sci. 24, 22^25.
[3] Stefanelli, C., Stanic, I., Bonavita, F., Flamigni, F., Pignatti, C.,
Guarnieri, C. and Caldarera, C.M. (1998) Biochem. Biophys.
Res. Commun. 243, 521^526.
[4] Durante, P., Gueuning, M.A., Darville, M.I., Hue, L. and Rous-
seau, G.G. (1999) FEBS Lett. 448, 239^243.
[5] Ariga, T., Jarvis, W.D. and Yu, R.K. (1998) J. Lipid Res. 39, 1^
16.
[6] Goswami, R. and Glyn, D. (2000) J. Neurosci. Res. 60, 141^149.
[7] Futerman, A.H., Boldin, S.A., Brann, A.B., Pelled, D., Meivar-
Levy, I. and Zisling, R. (1999) Biochem. Soc. Trans. 27, 432^437.
[8] Bla¤zquez, C., Galve-Roperh, I. and Guzma¤n, M. (2000) FASEB
J. 14, 2315^2322.
[9] Bla¤zquez, C., Sa¤nchez, C., Velasco, G. and Guzma¤n, M. (1998)
J. Neurochem. 71, 1597^1606.
[10] Galve-Roperh, I., Sa¤nchez, C., Corte¤s, M.L., Go¤mez del Pulgar,
T., Izquierdo, M. and Guzma¤n, M. (2000) Nat. Med. 6, 313^319.
[11] Bla¤zquez, C., Woods, A., Ceballos, M., Carling, D. and Guzma¤n,
M. (1999) J. Neurochem. 73, 1674^1682.
[12] Dickson, R.C., Lester, R.L. and Nagiec, M.M. (1999) Methods
Enzymol. 311, 3^9.
[13] Hanada, K., Hara, T. and Nishijima, M. (2000) J. Biol. Chem.
275, 8409^8415.
[14] Geelen, M.J.H., Bijleveld, C., Velasco, G., Wanders, R.J.A. and
Guzma¤n, M. (1997) Biochem. Biophys. Res. Commun. 233, 253^
257.
[15] Sprenkle, A.B., Davies, S.P., Carling, D., Hardie, D.G. and Stur-
gill, T.W. (1997) FEBS Lett. 403, 254^258.
[16] Kolesnick, R.N. and Kro«nke, M. (1998) Annu. Rev. Physiol. 60,
643^665.
[17] Hannun, Y.A. and Luberto, C. (2000) Trends Cell Biol. 10, 73^
80.
[18] Xu, J., Yeh, C.H., Chen, S., He, L., Sensi, S.L., Canzoniero,
L.M.T., Choi, D.W. and Hsu, C.Y. (1998) J. Biol. Chem. 273,
16521^16526.
[19] Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K.,
Fuks, Z. and Kolesnick, R. (1995) Cell 82, 405^414.
[20] Lehtonen, J.Y.A., Horiuchi, M., Daviet, L., Akishita, M. and
Dzau, V.J. (1999) J. Biol. Chem. 274, 16901^16906.
[21] Perry, D.K., Carton, J., Shah, A.K., Meredith, F., Uhlinger, D.J.
and Hannun, Y.A. (2000) J. Biol. Chem. 275, 9078^9084.
[22] Paumen, M.B., Ishida, Y., Muramatsu, M., Yamamoto, M. and
Honjo, T. (1997) J. Biol. Chem. 272, 3324^3329.
[23] Shimabukuro, M., Zhou, Y.T., Levi, M. and Unger, R.H. (1998)
Proc. Natl. Acad. Sci. USA 95, 2498^2502.
[24] Bazan, N.G. (1970) Biochim. Biophys. Acta 218, 1^10.
[25] Bazan, N.G. (1971) J. Neurochem. 18, 1379^1385.
[26] Bazan, N.G., Rodriguez de Turco, E.B. and Allan, G. (1995)
J. Neurotrauma 12, 791^814.
[27] Gao, G., Shamala Fernandez, C., Stapleton, D., Auster, A.S.,
Widmer, J., Dyck, J.R.B., Kemp, B.E. and Witters, L.A. (1996)
J. Biol. Chem. 271, 8675^8681.
[28] Stapleton, D., Mitchelhill, K.I., Gao, G., Widmer, J., Michell,
B.J., Teh, T., House, C.M., Shamala Fernandez, C., Cox, T.,
Witters, L.A. and Kemp, B.E. (1996) J. Biol. Chem. 271, 611^
614.
[29] Woods, A., Cheung, P.C.F., Smith, F.C., Davison, M.D., Scott,
J., Beri, R.K. and Carling, D. (1996) J. Biol. Chem. 271, 10282^
10290.
[30] Turnley, A.M., Stapleton, D., Mann, R.J., Witters, L.A., Kemp,
B.E. and Bartlett, P.F. (1999) J. Neurochem. 72, 1707^1716.
[31] Foretz, M., Carling, D., Guichard, C., Ferre¤, P. and Foufelle, F.
(1998) J. Biol. Chem. 273, 14767^14771.
[32] Leclerc, I., Kahn, A. and Doiron, B. (1998) FEBS Lett. 431, 180^
184.
[33] Velasco, G., Go¤mez del Pulgar, T., Carling, D. and Guzma¤n, M.
(1998) FEBS Lett. 439, 317^320.
FEBS 24540 25-1-01
C. Bla¤zquez et al./FEBS Letters 489 (2001) 149^153 153
